The new generation of monoamine oxidase inhibitors (Q28266471)

Europe PubMed Central

title

The new generation of monoamine oxidase inhibitors (English)

0 references

author name string

A M Cesura

1

0 references

A Pletscher

2

0 references

Andrea M. Cesura

1

0 references

Alfred Pletscher

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques

2

0 references

language of work or name

English

0 references

publication date

1992

0 references

published in

0 references

volume

38

0 references

page(s)

171-297

0 references

cites work

The discovery of antidepressants: a winding path

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Properties of monoamine oxidase (MAO) in human blood platelets, plasma, lymphocytes and granulocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

New directions in monoamine oxidase A and B selective inhibitors and substrates

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

An update on the identity crisis of monoamine oxidase: new and old evidence for the independence of MAO A and B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Biochemistry and genetics of monoamine oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The histochemical demonstration of monoamine oxidase activity by coupled peroxidatic oxidation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Topographic atlas of monoamine oxidase-containing neurons in the rat brain studied by an improved histochemical method

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Demonstration of monoamine oxidase type B in serotonergic and type A in noradrenergic neurons in the cat dorsal pontine tegmentum by an improved histochemical technique

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Distribution of two types of monoamine oxidase-containing neurons in the cat medulla oblongata demonstrated by an improved histochemical method

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Type B monoamine-oxidase-containing cells and fibers in the cat hypothalamus demonstrated by an improved enzyme histochemical method

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Demonstration of monoamine oxidase-A and -B in the human brainstem by a histochemical technique

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Histochemical localisation of monoamine oxidase A and B in rat brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Distinct monoamine oxidase A and B populations in primate brain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Immunocytochemical localization of monoamine oxidases A and B in human peripheral tissues and brain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Localization of distinct monoamine oxidase a and monoamine oxidase b cell populations in human brainstem

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Topographic immunocytochemical mapping of monoamine oxidase-A, monoamine oxidase-B and tyrosine hydroxylase in human post mortem brain stem

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: characterization and localization of receptor binding sites in rat and human brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

High-affinity binding sites for [3H]MPTP may correspond to monamine oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Localization in rat brain of binding sites for parkinsonian toxin MPTP: similarities with [3H]pargyline binding to monoamine oxidase.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Molecular neuroanatomy of monoamine oxidases in human brainstem

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Quantitative localization of human brain monoamine oxidase B by large section autoradiography using L-[3H]deprenyl.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The histochemical demonstration of monoamine oxidase-containing neurons in the human hypothalamus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Immunohistochemical evidence for the presence of type B monoamine oxidase in histamine-containing neurons in the posterior hypothalamus of cats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Distribution of type B monoamine oxidase immunoreactivity in the cat brain with reference to enzyme histochemistry

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

[3H]Ro 19-6327: a reversible ligand and affinity labelling probe for monoamine oxidase-B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Localization of monoamine oxidase B in human brain by autoradiographical use of 11C-labelled L-deprenyl

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Turnover of brain monoamine oxidase measured in vivo by positron emission tomography using L-[11C]deprenyl.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The effect of age on the activity and molecular properties of human brain monoamine oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Differential changes in monoamine oxidase A and B activity in the aging rat brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Differences between monoamine oxidase concentrations in striatum and forebrain of aged and young rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Monoamine oxidase, brain ageing and degenerative diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Dopamine turnover and glutathione oxidation: implications for Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Intramitochondrial formation of oxidized glutathione during the oxidation of benzylamine by monoamine oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Dopaminergic system and monoamine oxidase-B activity in Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Expression of monoamine oxidase B activity in astrocytes of senile plaques.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Biochemistry and pharmacology of moclobemide, a prototype RIMA

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Blood-brain barrier monoamine oxidase: enzyme characterization in cerebral microvessels and other tissues from six mammalian species, including human.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Methylhistamine: evidence for selective deamination by MAO B in the rat brain in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Interactions of monoamine oxidase with substrates and inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Dopamine is a monoamine oxidase B substrate in man.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Some observations upon a new inhibitor of monoamine oxidase in brain tissue.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Kinetic studies and effects in vivo of a new monoamine oxidase inhibitor, N[2(ochlorophenoxy)-ethyl]-cyclopropylamine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Multiple Forms of Rat Brain Monoamine Oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Structural Features of Human Monoamine Oxidase A Elucidated from cDNA and Peptide Sequences

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The primary structure of bovine monoamine oxidase type A. Comparison with peptide sequences of bovine monoamine oxidase type B and other flavoenzymes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Molecular cloning of a cDNA for rat liver monoamine oxidase B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Primary structure of rat monoamine oxidase A deduced from cDNA and its expression in rat tissues

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Molecular biological studies of monoamine oxidase: structure and function

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Molecular properties of monoamine oxidases A and B

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Prediction of the occurrence of the ADP-binding beta alpha beta-fold in proteins, using an amino acid sequence fingerprint

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

NADPH-cytochrome P-450 oxidoreductase: flavin mononucleotide and flavin adenine dinucleotide domains evolved from different flavoproteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The covalently-bound flavin of hepatic monoamine oxidase. 1. Isolation and sequence of a flavin peptide and evidence for binding at the 8alpha position

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Bovine liver monoamine oxidase. A modified purification procedure and preliminary evidence for two subunits and one FAD

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Differences in the Structure of A and B Forms of Human Monoamine Oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Monoamine oxidase A from human placenta and monoamine oxidase B from bovine liver both have one FAD per subunit

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Monoamine oxidases A and B as components of a membrane complex.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Selective Effects of Proteases and Phospholipase A2 on Monoamine Oxidases A and B of Human Brain and Liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Expression of functional human monoamine oxidase A and B cDNAs in mammalian cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Catalytically active monoamine oxidase type A from human liver expressed in Saccharomyces cerevisiae contains covalent FAD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Effect of riboflavin on monoamine oxidase activity in cultured neuroblastoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The in vitro insertion of monoamine oxidase B into mitochondrial outer membranes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

A 70-kd protein of the yeast mitochondrial outer membrane is targeted and anchored via its extreme amino terminus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Mitochondrial protein import

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The vectorial orientation of human monoamine oxidase in the mitochondrial outer membrane

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Genetics of mitochondrial biogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Protein translocation across membranes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

In vitro synthesis of monoamine oxidase of rat liver outer mitochondrial membrane

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Gene for monoamine oxidase type A assigned to the human X chromosome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Assignment of genes for human monoamine oxidases A and B to the X chromosome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Human monoamine oxidase gene (MAOA): chromosome position (Xp21-p11) and DNA polymorphism

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Localization of human monoamine oxidase-A gene to Xp11.23-11.4 by in situ hybridization: Implications for norrie disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Human monoamine oxidase A and B genes map to Xp 11.23 and are deleted in a patient with Norrie disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Submicroscopic interstitial deletion of the X chromosome explains a complex genetic syndrome dominated by Norrie disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Monoamine oxidase deficiency in males with an X chromosome deletion

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Human monoamine oxidase A and B genes exhibit identical exon-intron organization

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Structure of the human gene for monoamine oxidase type A.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Species differences in monoamine oxidase-A and -B as revealed by sensitivity to trypsin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

A new type of mitochondrial monoamine oxidase distinct from type-A and type-B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Platelet MAO concentration and molecular activity: II. Comparison of normal and schizophrenic populations

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Partial amino acid sequence analysis of human placenta monoamine oxidase A and bovine liver monoamine oxidase B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Molecular genetics of the monoamine oxidases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

On the substrate specificities of the two forms of monoamine oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Substrate selectivity of type A and type B monoamine oxidase in rat brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Structure-modulated recognition of substrates and inhibitors by monoamine oxidases A and B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The effects of 5-HT uptake- and MAO-inhibitors on L-5-HTP-induced excitation in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

A kinetic evaluation of monoamine oxidase activity in rat liver mitochondrial outer membranes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Monoamine oxidase in sympathetic nerves: a transmitter specific enzyme type

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Multiple binding sites of human brain and liver monoamine oxidase: substrate specificities, selective inhibitions, and attempts to separate enzyme forms

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Monoamine oxidase type A: differences in selectivity towards l-norepinephrine compared to serotonin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Differential effects of clorgyline on catecholamine and indoleamine metabolites in the cerebrospinal fluid of rhesus monkeys

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Influence of harmaline on the ability of pargyline to alter catecholamine metabolism in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Epinephrine accumulation in rat brain after chronic administration of pargyline and LY 51641--comparison with other brain amines.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Preferential deamination of dopamine by an A type monoamine oxidase in rat brain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Rhesus monkey cerebrospinal fluid amine metabolite changes following treatment with the reversible monoamine oxidase type-A inhibitor cimoxatone

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The effects of amiflamine on cerebrospinal fluid amine metabolites in the rhesus monkey

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Rapid screening assay for revertants derived from MSV-transformed cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Deamination of dopamine and its 3-O-methylated derivative by human brain monoamine oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Phenylethylaminergic modulation of catecholaminergic neurotransmission

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Marked amine and amine metabolite changes in Norrie disease patients with an X-chromosomal deletion affecting monoamine oxidase.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Plasma amine oxidase activities in Norrie disease patients with an X-chromosomal deletion affecting monoamine oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The oxidation of dopamine by the semicarbazide-sensitive amine oxidase (SSAO) from rat vas deferens

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Pargyline Prevents MPTP-Induced Parkinsonism in Primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Prevention of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic toxicity in mice by MDL 72145, a selective inhibitor of MAO-B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Further insight into the mode of action of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Stopped-flow studies on the mechanism of oxidation of N-methyl-4-phenyltetrahydropyridine by bovine liver monoamine oxidase B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Mechanism-based inactivation of monoamine oxidases A and B by tetrahydropyridines and dihydropyridines

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Uptake, release, and subcellular localization of 1-methyl-4-phenylpyridinium in blood platelets

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Astroglial ablation prevents MPTP-induced nigrostriatal neuronal death.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as monoamine oxidase substrates: a second ring is not necessary

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Formation of the neurotransmitter glycine from the anticonvulsant milacemide is mediated by brain monoamine oxidase B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The novel neuropsychotropic agent milacemide is a specific enzyme-activated inhibitor of brain monoamine oxidase B

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Microionophoretic study with milacemide, a glycine precursor, on mammalian central nervous system cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Is the oxidation of milacemide by monoamine oxidase a major factor in its anticonvulsant actions?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Novel substrates and products of amine oxidase-catalysed reactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The Reaction Pathway of Pig Brain Mitochondrial Monoamine Oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The interaction between human platelet monoamine oxidase, its monoamine substrates and oxygen

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Kinetic studies on the catalytic mechanism of liver monoamine oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Human brain monoamine oxidase type B: mechanism of deamination as probed by steady-state methods

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The kinetic mechanisms of monoamine oxidases A and B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The interaction of monoamine oxidases with tertiary amines

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The use of mechanism-based inactivators to probe the mechanism of monoamine oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Mechanism-based inactivation of mitochondrial monoamine oxidase by N-(1-methylcyclopropyl)benzylamine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Mechanism of inactivation of monoamine oxidase by 1-phenylcyclopropylamine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

1-Phenylcyclobutylamine, the first in a new class of monoamine oxidase inactivators. Further evidence for a radical intermediate

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Identification of the amino acid bound to the labile adduct formed during inactivation of monoamine oxidase by 1-phenylcyclopropylamine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Inactivation of monoamine oxidase A by the monoamine oxidase B inactivators 1-phenylcyclopropylamine, 1-benzylcyclopropylamine, and N-cyclopropyl-alpha-methylbenzylamine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Deuterium isotope effects in relation to the chemical mechanism of monoamine oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Deuterium isotope effects on the enzymatic oxidative deamination of trace amines

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Stereospecific deuterium substitution at the alpha-carbon position of dopamine and its effect on oxidative deamination catalyzed by MAO-A and MAO-B from different tissues

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Evidence for Essential Histidine Residues in Bovine‐Liver Mitochondrial Monoamine Oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Monoamine oxidase. I. Specificity of some substrates and inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Enzyme-activated irreversible inhibitors of monoamine oxidase: phenylallylamine structure-activity relationships

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The rational design of suicide substrates of amine oxidases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Suicide substrates, mechanism-based enzyme inactivators: recent developments

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Kinetics of suicide substrates

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Rates of recovery of irreversibly inhibited monoamine oxidases: a measure of enzyme protein turnover.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Monoamine oxidase: an approximation of turnover rates

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Cumulative effects of irreversible MAO inhibitors in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Time-dependent inhibition of monoamine oxidase by beta-phenethylamine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

In vivo inhibition of liver and brain monoamine oxidase by 1-Isonicotinyl-2-isopropyl hydrazine.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Deuterium isotope effect of phenelzine on the inhibition of rat liver mitochondrial monoamine oxidase activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Monoamine oxidase inhibitor withdrawal phenomena: symptoms and pathophysiology

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

N-substituted cyclopropylamines as inhibitors of MAO-A and -B forms

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Substrate-selective monoamine oxidases—inhibitor, tissue, species and functional differences

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Selective inhibitors of monoamine oxidase A and B: biochemical, pharmacological, and clinical properties

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Comparative behavioral effects of clorgyline and pargyline in man: A preliminary evaluation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The structure of the covalent adduct formed by the interaction of 3-dimethylamino-1-propyne and the flavine of mitochondrial amine oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Titration of human brain monoamine oxidase -A and -B by clorgyline and L-deprenil

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Determination of monoamine oxidase concentrations in rat liver by inhibitor binding

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The kinetics of monoamine oxidase inhibition by three 2-indolylmethylamine derivatives.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The effects of chronic regimens of clorgyline and pargyline on monoamine metabolism in the rat brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Saturation of monoamine oxidase by intraneuronal noradrenaline accumulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Modification of vesicular dopamine and norepinephrine by monoamine oxidase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Modulation of vocal and nonvocal behavior in adult squirrel monkeys by selective MAO-A and MAO-B inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Minipump clorgyline administration and CSF amine metabolites in unrestrained monkeys

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Effect of chronic ritanserin or clorgyline on amine and metabolite levels in rat frontal cortex.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Release of endogenous dopamine from rat isolated striatum: effect of clorgyline and (-)-deprenyl

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Trans-striatal dialysis coupled to reverse phase high performance liquid chromatography with electrochemical detection: a new method for the study of the in vivo release of endogenous dopamine and metabolites.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Dopamine-β-hydroxylase and norepinephrine in human cerebrospinal fluid: Effects of monoamine oxidase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Central and peripheral dopamine beta hydroxylase: responses to long term treatment with monoamine oxidase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Chronic antidepressant administration decreases the expression of tyrosine hydroxylase in the rat locus coeruleus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Chronic effects of a monoamine oxidase-inhibiting antidepressant: decreases in functional alpha-adrenergic autoreceptors precede the decrease in norepinephrine-stimulated cyclic adenosine 3': 5'-monophosphate systems in rat brain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Changes in α- and β-receptor densities in rat brain as a result of treatment with monoamine oxidase inhibiting antidepressants

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Antidepressant drugs and down-regulation of presynaptic receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Chronic clonidine treatment produces desensitisation of post- but not presynaptic alpha 2-adrenoceptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The effect of clorgyline on noradrenergic function

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Possible subsensitization of alpha 2-adrenergic receptors by chronic monoamine oxidase inhibitor treatment in psychiatric patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Correlation of changes in α2-adrenoceptor number and locomotor responses to clonidine following clorgyline discontinuation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Decrease in [3H]-serotonin binding in rat brain produced by the repeated administration of either monoamine oxidase inhibitors or centrally acting serotonin agonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Chronic clorgyline treatment enhances release of norepinephrine following sympathetic stimulation in the rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Chronic inhibition of monoamine oxidase reduces noradrenaline release in rat vas deferens and anococcygeus muscle

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Sigma binding sites in the brain; an emerging concept for multiple sites and their relevance for psychiatric disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Lifetime monoamine oxidase inhibition and sleep.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Monoamine oxidase inhibitors prevent striatal neuronal necrosis induced by transient forebrain ischemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Effects of transient forebrain ischemia and pargyline on extracellular concentrations of dopamine, serotonin, and their metabolites in the rat striatum as determined by in vivo microdialysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Selective inhibition of MAO-A but not MAO-B activity increases rat pineal melatonin

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Effect of selective monoamine oxidase inhibitors on rat pineal melatonin synthesis in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Possible melatonin involvement in the hypotensive effect of MAO inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The effect of monoamine oxidase A and B inhibitors on rat serum prolactin

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Effects of clorgyline and deprenil on corticosterone levels in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Deprenil: loss of selectivity for inhibition of B-type MAO after repeated treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The effect of long-term treatment with deprenyl on basal and L-dopa evoked dopamine release in vitro from the corpus striatum of aged rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Determination of 2-phenylethylamine in rat brain after MAO inhibitors, and in human CSF and urine by capillary GC and chemical ionization MS

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Monoamine oxidase-B inhibition: a comparison of in vivo and ex vivo measures of reversible effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Deprenyl suppresses the oxidant stress associated with increased dopamine turnover

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

(-) deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Maintenance on L-deprenyl prolongs life in aged male rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The pharmacology of Parkinson's disease: basic aspects and recent advances

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Deprenyl is metabolized to methamphetamine and amphetamine in man

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Evidence that deprenyl, A type B monoamine oxidase inhibitor, is an indirectly acting sympathomimetic amine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The regulation of striatal DOPA synthesis by α2-adrenoreceptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Evidence for existence of two opposite noradrenergic brain systems controlling behavior

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The monoamine oxidase inhibitors clorgyline and L-deprenyl also affect the uptake of dopamine, noradrenaline and serotonin by rat brain synaptosomal preparations

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ?cheese effect?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of L-deprenyl and MDL 72145.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Tyramine-induced noradrenaline release from rat brain slices: prevention by (-)-deprenyl

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Postmortem tissue methamphetamine concentrations following selegiline administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Investigation on central dopaminergic receptors (D-2) using the antagonistic properties of new benzamides.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

(Z)-2-(2,4-Dichlorophenoxy)methyl-3-fluoroallylamine (MDL 72638): a clorgyline analogue with surprising selectivity for monoamine oxidase type B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

(E)-2-(3,4-dimethoxyphenyl)-3-fluoroallylamine: a selective, enzyme-activated inhibitor of type B monoamine oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

MDL 72145, an enzyme-activated irreversible inhibitor with selectivity for monoamine oxidase type B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Selective inhibition of monoamine oxidase type B by MDL 72145 increases the central effects of L-dopa without modifying its cardiovascular effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Inhibition of monoamine oxidase selectively in brain monoamine nerves using the bioprecursor (E)-beta-fluoromethylene-m-tyrosine (MDL 72394), a substrate for aromatic L-amino acid decarboxylase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Monoamine receptor sensitivity changes following chronic administration of MDL 72394, a site-directed inhibitor of monoamine oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Selective inactivation of MAO-B by benzyl-dimethyl-silyl-methanamines in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Reversible, enzyme-activated monoamine oxidase inhibitors: new advances

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

On the reversibility of reversible MAO inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16-6491.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Brain microdialysis in rats: a technique to reveal competition in vivo between endogenous dopamine and moclobemide, a RIMA antidepressant

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The effects of lifelong treatment with MAO inhibitors on amino acid levels in rat brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Effect of brofaromine and pargyline on human plasma melatonin concentrations

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Moclobemide, an inhibitor of MAO-A, does not increase daytime plasma melatonin levels in normal humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Biotransformation of moclobemide in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Pharmacokinetic and metabolic aspects of the moclobemide-food interaction

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: evidence for selective and reversible inhibition of monoamine oxidase type A in vivo but not in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Binding of [3H]Ro 16-6491, a reversible inhibitor of monoamine oxidase type B, to human brain mitochondria and platelet membranes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Interactions of the novel inhibitors of MAO-B Ro 19-6327 and Ro 16-6491 with the active site of the enzyme

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

[3H]Ro 16-6491, a selective probe for affinity labelling of monoamine oxidase type B in human brain and platelet membranes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The monoamine oxidase inhibiting properties of CGP 11305 A.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Reversibility of the interaction of CGP 11305 A with MAO A in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The inhibition of monoamine oxidase by brofaromine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Binding of [3H]brofaromine to monoamine oxidase A in vivo: displacement by clorgyline and moclobemide.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The reversible MAO inhibitor, brofaromine, inhibits serotonin uptake in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Brofaromine - a Selective, Reversible, and Short-Acting MAO-A Inhibitor: Review of the Pharmacological and Clinical Findings

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Determination of the new monoamine oxidase inhibitor brofaromine and its major metabolite in biological material by gas chromatography with electron-capture detection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Metabolic fate of 3-(3-methylphenyl)-5-hydroxymethyl-2-oxazolidinone (toloxatone), a new antidepressant agent, in man

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Characteristics of the Inhibition of Rat Brain Monoamine Oxidase In Vitro by MD780515

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Cimoxatone is a reversible tight-binding inhibitor of the A form of rat brain monoamine oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Antagonism between long acting monoamine oxidase inhibitors (MAOI) and MD780515, a new specific and reversible MAOI

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The deamination of noradrenaline and 5-hydroxytryptamine by rat brain and heart monoamine oxidase and their inhibition by cimoxatone, toloxatone and MD 770222.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Plasma protein binding of the reversible type a MAO inhibitor cimoxatone (MD 780515)

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Different stereoselective inhibition of monoamine oxidase-B by the R- and S-enantiomers of MD 780236

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Metabolism of the monoamine oxidase-B inhibitor, MD 780236 and its enantiomers by the A and B forms of the enzyme in the rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Effects of acute and repeated administration of amiflamine on monoamine oxidase inhibition in the rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Selective inhibition by amiflamine of monoamine oxidase type A in rat brain, liver and duodenum.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Effect of repeated amiflamine administration on serotonergic and noradrenergic neurotransmission: electrophysiological studies in the rat CNS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

3HHarmaline as a specific ligand of MAO A--I. Properties of the active site of MAO A from rat and bovine brains

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

[3H]harman binding experiments. I: A reversible and selective radioligand for monoamine oxidase subtype A in the CNS of the rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

[3H]harman binding experiments. II: Regional and subcellular distribution of specific [3H]harman binding and monoamine oxidase subtypes A and B activity in marmoset and rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The effect of tryptolines (1, 2, 3, 4-tetrahydro-β-carbolines) on monoamine metabolism and the platelet aggregation response in human platelets

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Neuroamine-derived alkaloids: Substrate-preferred inhibitors of rat brain monoamine oxidase in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Inhibition of monoamine oxidases A and B by simple isoquinoline alkaloids: racemic and optically active 1,2,3,4-tetrahydro-, 3,4-dihydro-, and fully aromatic isoquinolines

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Endogenous inhibitors of monoamine oxidase present in human cerebrospinal fluid

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

A monoamine oxidase inhibitor in human urine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Distribution of endogenous benzodiazepine receptor ligand-monoamine oxidase inhibitory activity (tribulin) in tissues.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

New endogenous benzodiazepine receptor ligand in human urine: Identity with endogenous monoamine oxidase inhibitor?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Isatin: Identity with the Purified Endogenous Monoamine Oxidase Inhibitor Tribulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Urinary output of endogenous monoamine oxidase inhibitor and isatin during acute migraine attacks

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Serotonergic effects of isatin: an endogenous MAO inhibitor related to tribulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Efficacy of moclobemide in different patient groups: a meta-analysis of studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Do autoreceptors mediate dopamine agonist — induced yawning and suppression of exploration? A critical review

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Moclobemide and clomipramine in the treatment of depression. A randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

A Placebo-controlled Study of the Antidepressant Activity of Moclobemide,A New MAO-A Inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

A controlled study of a specific MAO A reversible inhibitor (R011-1163) and amitriptyline in depressive illness

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

A Comparison of Moclobemide and Imipramine in Treatment of Depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Moclobemide and clomipramine in endogenous depression. A randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Moclobemide versus clomipramine in endogenous depression. A double-blind randomised clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Moclobemide and clomipramine in reactive depression. A placebo-controlled randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The effects of moclobemide on nocturnal sleep of depressed patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Use of moclobemide in children with attention deficit hyperactivity disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Cardiocirculatory effects of moclobemide (Ro 11-1163), a new reversible, a short-acting MAO-inhibitor with preferential type A inhibition, in healthy volunteers and depressive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Effects of moclobemide and mianserin on highway driving, psychometric performance and subjective parameters, relative to placebo

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Behavioural toxicity of antidepressants with particular reference to moclobemide

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

A double blind trial of moclobemide versus amitriptyline in the treatment of depressive disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Moclobemide, a new reversible MAO inhibitor--interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Evaluation and comparison of the interaction between alcohol and moclobemide or clomipramine in healthy subjects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Influence of moclobemide on ibuprofen-induced faecal blood loss

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Tyramine pressor response with moclobemide--a reversible monoamine oxidase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Interaction between moclobemide and oral tyramine in depressed patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Potentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Clinical pharmacology of moclobemide, a new reversible monoamine oxidase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Brofaromine vs. maprotiline plus lithium in treatment-resistant depressed outpatients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Effects of brofaremine (CGP 11 305A), a short-acting, reversible, and selective inhibitor of MAO-A on sleep, nocturnal penile tumescence and nocturnal hormonal secretion in three healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Clorgyline. A new treatment for patients with refractory rapid-cycling disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Psychophysiological changes during pharmacological treatment of patients with obsessive compulsive disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Treatment of hyperactive children with monoamine oxidase inhibitors. I. Clinical efficacy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

REM sleep suppression induced by selective monoamine oxidase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Oral absorption and concentration-effect relationship of tyramine with and without cimoxatone, a type-A specific inhibitor of monoamine oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Different effects of serotonin (5-HT) uptake blockers in caudate nucleus and hippocampus of the rabbit: Role of monoamine oxidase in dopaminergic terminals

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Deprenyl in Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Selegiline in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Effect of deprenyl on the progression of disability in early Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Deprenyl for the treatment of early Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Deprenyl in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Long term treatment with L-deprenyl.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

L-deprenyl treatment of on-off phenomena in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Experiences with L-deprenyl in Parkinsonism

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The effect of L-Deprenyl on on-off phenomena in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Deprenyl in Parkinson disease: personal experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Multicenter trial of L-Deprenyl in Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The facilitation of dopaminergic activity in the aged brain by (-)deprenyl. A proposal for a strategy to improve the quality of life in senescence

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Lisuride plus selegiline in the treatment of early Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

A double-blind, controlled study of high-dose L-deprenyl in the treatment of Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

L-deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

l-Deprenyl in atypical depressives.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Antidepressant potentiation of 5-hydroxytryptophan by L-deprenil in affective illness

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

L-deprenyl plus L-phenylalanine in the treatment of depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Brief information on an early phase-II study with deprenyl in demented patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Cognitive effects of L-deprenyl in Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Effects of a MAO-B inhibitor in the treatment of Alzheimer disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

A possible L-deprenyl induced hypertensive reaction

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Tyramine pressor sensitivity changes during deprenyl treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Possible interactions between deprenyl and prozac.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Severe adverse interaction between pethidine and selegiline

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Evidence that the reversible MAO-A inhibitor moclobemide increases prolactin secretion by a serotonergic mechanism in healthy male volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

High urinary norepinephrine excretion in major depressive disorders: effects of a new type of MAO inhibitor (Moclobemide, RO 11-1163)

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Urinary excretion of O-methylated catecholamines, tyramine and phenyl-ethylamine by volunteers treated with tranylcypromine and CGP 11305 A

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Effect of Low-Dose Clorgyline on 24-Hour Urinary Monoamine Excretion in Patients With Rapidly Cycling Bipolar Affective Disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Common mechanism of action of biochemically “specific” antidepressants

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Treatment of hyperactive children with monoamine oxidase inhibitors. II. Plasma and urinary monoamine findings after treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Dissociation of norepinephrine turnover from alpha-2 responses after clorgiline

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Effects of Antidepressant Treatments on Dopamine Turnover in Depressed Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The effects of antidepressants on the cerebrospinal fluid homovanillic acid/5-hydroxyindoleacetic acid ratio

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Growth hormone response to clonidine unchanged by chronic clorgyline treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Effect of long-term clorgyline administration on human platelet alpha-adrenergic receptor binding and platelet cyclic AMP responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Human plasma melatonin is elevated during treatment with the monoamine oxidase inhibitors clorgyline and tranylcypromine but not deprenyl

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Effect of a reversible and selective MAO-A inhibitor (cimoxatone) on diurnal variation in plasma prolactin level in man

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

2-Phenylethylamine and Amphetamine in Human Brain: Effects of l-Deprenyl in Parkinson's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Alzheimer's disease and senile dementia: biochemical characteristics and aspects of treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Biochemical effects of L-deprenyl in atypical depressives

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Platelet monoamine oxidase inhibition by deprenyl and tranylcypromine: implications for clinical use

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

Metabolism of monoamine oxidase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3

MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7141-9_3